ACRUX Ltd - Asset Resilience Ratio
ACRUX Ltd (ACR) has an Asset Resilience Ratio of 11.94% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of ACRUX Ltd to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2023)
This chart shows how ACRUX Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of ACRUX Ltd.
Liquid Assets Composition Over Time
This chart breaks down ACRUX Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read debt load of ACRUX Ltd for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$863.00K | 11.94% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$863.00K | 11.94% |
Asset Resilience Insights
- Moderate Liquidity: ACRUX Ltd has 11.94% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
ACRUX Ltd Industry Peers by Asset Resilience Ratio
Compare ACRUX Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Genscript Biotech Corporation
F:G51 |
Biotechnology | 13.79% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
89bio Inc
NASDAQ:ETNB |
Biotechnology | 71.60% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 2.66% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
Annual Asset Resilience Ratio for ACRUX Ltd (2016–2023)
The table below shows the annual Asset Resilience Ratio data for ACRUX Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-06-30 | 20.98% | AU$3.00 Million ≈ $2.12 Million |
AU$14.30 Million ≈ $10.12 Million |
+1.34pp |
| 2022-06-30 | 19.64% | AU$3.00 Million ≈ $2.12 Million |
AU$15.27 Million ≈ $10.81 Million |
-13.41pp |
| 2021-06-30 | 33.06% | AU$8.00 Million ≈ $5.66 Million |
AU$24.20 Million ≈ $17.12 Million |
-10.14pp |
| 2020-06-30 | 43.19% | AU$8.00 Million ≈ $5.66 Million |
AU$18.52 Million ≈ $13.10 Million |
-30.48pp |
| 2019-06-30 | 73.67% | AU$18.00 Million ≈ $12.74 Million |
AU$24.43 Million ≈ $17.29 Million |
-11.28pp |
| 2018-06-30 | 84.95% | AU$27.60 Million ≈ $19.53 Million |
AU$32.49 Million ≈ $22.99 Million |
+34.54pp |
| 2017-06-30 | 50.41% | AU$23.85 Million ≈ $16.87 Million |
AU$47.31 Million ≈ $33.47 Million |
-- |
| 2016-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$53.37 Million ≈ $37.76 Million |
-- |
About ACRUX Ltd
Acrux Limited, together with its subsidiaries, develops and commercializes generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally. The company provides estradiol transdermal sprays to women for the treatment of flushes associated with menopause under the Evamist and Lenzetto brand names; Dapsone 5% and Dapsone 7.5%, which are gels for th… Read more